Trending...
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community
- LiteracyNation's 3rd Annual Indie Author Book Fair
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.
SAN DIEGO - PennZone -- About John Burd, PhD:
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
More on The PennZone
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
More on The PennZone
4930 Bradshaw Court, San Diego, CA 92130
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
More on The PennZone
- Move in this Fall! New Released Quick Move-In Townhomes at Heritage at South Brunswick with Limited-Time Incentives
- Rebecca L. Francis, Founder of the Rebecca Francis Team, Named to Lehigh Valley Business' LVB 300
- Crossroads4Hope Marks 25 Years Ensuring No One Faces Cancer Alone At its Inspiring Hope Gala
- Imagen Golf & Top 100 Coach Daniel Guest Voted Best Golf Instruction Firm of the Year 2026
- Q1 2026 Arizona Technology Industry Impact Report Recaps Advanced Manufacturing Growth, High-Value Jobs and Workforce Investment
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
More on The PennZone
- Former Prosecutor Opens Stegall Law in Summerville
- Vboost Celebrates 14 years of Automotive Viral Marketing
- M.C. Weeks, Inc. Marks 80 Years of Family Ownership and Brand Refresh
- Ignazio Arces Wins Stevie® Award for Maverick of the Year at the 2026 International Business Awards
- SMACK Fighting Championships Debuts a New Sports Concept in Philadelphia
4930 Bradshaw Court, San Diego, CA 92130
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Source: Beneficience.com Legacy PR
0 Comments
Latest on The PennZone
- Nola Blue Records to Release John Németh's Illinois Central in March 2027
- ImagineX Named to 2026 Inc. 5000 List of America's Fastest-Growing Private Companies
- ASSIST Software Becomes One of the First European Companies Certified to ISO/IEC 42001
- The World's No.1 Superstar® Enters the Occult with New Track and Cinematic Visual "Under Your Spell"
- PricZone Launches Online Shopping Platform Offering Electronics, Gaming, and More
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community
- Lineus Medical Elevates Leadership to Accelerate Growth After Breakthrough Clinical Results
- Gateway Center Arena Announces Duane Curry as General Manger
- Mumbai Central Farmers Market Launches Community Collective for More Value and Connection
- XRPPower Expands Platform Security With Enhanced Brand Protection and Official Verification Standards
- Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States
- Birkdale Investments LLC Acquires Assets of Mumbai Central Farmers Market, Unveils Expanded Vision
- RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
- The City's Most Elegant Open-Air Dinner Party Returns September 12, 2026
- LiteracyNation's 3rd Annual Indie Author Book Fair
- FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
- Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
- Loud! OOH calls for prize draw advertising standards as £1.3bn category moves outdoors